Phase II study comparing combination therapy with carboplatin plus pemetrexed vs combination therapy with pemetrexed plus bevacizumab in chemo-naive elderly patients with advanced non-squamous non-small-cell lung cancer (HSR1402).
- Conditions
- advanced non-squamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000014302
- Lead Sponsor
- Hamamatsu Univ. School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 64
Not provided
1. squamous histology 2. interstitial lung disease or pulmonary fibrosis 3. presence or history of hemoptysis 4. pleural effusion or cardiac effusion that needs to be treated 5. superior vena cava syndrome 6. uncontrolled and symptomatic brain metastasis except stable brain metastases after radiotherapy 7. uncontrolled diabetes, hypertension, liver damage, ischemic heart disease or myocardial infarction within three months. 8. severe infectious disease 9 pregnancy, lactation, or willing to get pregnant. 10. active malignancy of other organ. 11.history of severe hypersensitivity to drugs 12. bleeding diathesis or coagulopathy 13. symptomatic cerebrovascular disease, or history of brain attack 12 months prior to the study. 14. uncontrolled digestive ulcer or history of gastrointestinal perforation. 15. other severe comorbidities 16. judgement of discontinuation by attending physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method